Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2019-07-30 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于获得奥美沙坦酯片药品注册批件的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a drug registration approval from the National Medical Products Administration (国家药品监督管理局). It details the drug's registration information, approval status, and related product information. The text is short (1192 characters) and focuses on regulatory approval and product launch information rather than financial data, management changes, or shareholder matters. It does not contain financial statements, earnings data, or meeting materials. This type of announcement is a regulatory update about product approval, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2019-07-30 Chinese
关于控股股东部分股权解除质押的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the release of pledged shares by the company's controlling shareholder. It details the number of shares released from pledge, dates, and related procedures. There is no financial data, no discussion of financial results, no management commentary, and no mention of a report being attached or published. The content is about a change in share pledge status, which relates to capital structure but is more specifically about share pledge release. This fits best under Capital/Financing Update (CAP) as it concerns financing activities related to share pledges.
2019-07-23 Chinese
关于控股股东股权质押的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the pledge of shares by the controlling shareholder of Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the number of shares pledged, the pledge period, the pledgee, and the impact on shareholding percentages. The document is an announcement of a financing-related event (share pledge) by a major shareholder, not a full financial report or audit. It does not contain financial statements or management discussion but focuses on share pledge details. This fits the category of Capital/Financing Update (CAP). The document length is short (1343 characters), and it is not merely announcing a report publication but providing substantive information about the share pledge event.
2019-07-11 Chinese
关于全资子公司完成工商变更登记的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding the completion of a business registration change for a wholly-owned subsidiary of the company. It includes details about the subsidiary's new name, legal representative, registered capital, and business scope. There is no financial data, no mention of financial results, no voting results, no management changes, and no regulatory certifications. The document is brief (714 characters) and serves as a formal notification of a corporate administrative update. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2019-05-27 Chinese
关于控股股东部分股权解除质押的公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from Shenzhen Xintai Pharmaceutical Co., Ltd. regarding the release of a portion of pledged shares held by the controlling shareholder. It details the number of shares released from pledge, dates, pledgee information, and cumulative pledge status. The document is short (1367 characters) and focuses on share pledge status changes, which is a capital structure update. There is no financial data, earnings, or management discussion. It is not an annual or interim report, nor an earnings release. It is not a voting result or AGM material. The content fits best under Capital/Financing Update (CAP) as it relates to changes in share pledge status, a financing-related activity.
2019-05-14 Chinese
关于控股股东股权质押的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding the pledge of shares by the company's controlling shareholder. It details the number of shares pledged, the pledge period, the pledgee, and the impact on shareholding percentages. There is no financial data, earnings information, or management discussion. The document is a formal disclosure about a shareholder's share pledge, which fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about share pledge status and does not fit into more specific categories like Capital/Financing Update or Major Shareholding Notification since it focuses on pledge rather than ownership change or capital raising.
2019-04-25 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.